香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 Sisram Medical Ltd 復䢇醫療科技有限公司* （ 於 以 色 列 註 冊 成 立 的 有 限 公 司 ） （股份代號：1696） 有關商業配送合作協議之 持續關連交易 商業配送合作協議 董事會欣然宣佈，於二零二五年九月二十二日，復銳（天津）與復星萬邦（江蘇） 訂立商業配送合作協議，據此，復銳（天津）同意負責該產品於區域的（其中包 括）商業化、市場推廣、醫學教育及商業計劃服務（「服務」），而復星萬邦（江蘇） 則同意負責（其中包括）該產品於區域的進口、採購、清關、法檢、倉儲運輸、商 業渠道配送及一般分銷。 該產品（注射用A型肉毒毒素(DaxibotulinumtoxinA-lanm)，中國內地商標為達 希斐®，英文商標為DAXXIFY®，項目編號RT002）為一款由復星產業再授權的 產品，用於暫時性改善成人因皺眉肌及╱或降眉間肌活動引起的中度至重度皺 眉紋。 訂立商業配送合作協議的理由及裨益 ...

Sales Performance - In the first half of 2025, Sisram Medical achieved a 7.1% year-on-year growth in international sales channels, demonstrating resilience despite macroeconomic challenges [20]. - The company reported a significant 17.6% double-digit growth in the Asia-Pacific market, driven by strong performance in Thailand and South Korea [20]. - Revenue for the six months ended June 30, 2025, was $165,476,000, a decrease of 1.5% compared to $168,730,000 for the same period in 2024 [99]. - Revenue from the medical aesthetics product line was $137.7 million, accounting for 83.2% of total revenue, down 7.8% from $149.3 million in the previous year, influenced by economic challenges in North America, the Middle East, and Africa [55]. - Revenue from the Asia-Pacific region increased to $65,825,000, up 17.7% from $55,953,000 in the prior year [114]. - North America revenue decreased by 15.6% to $56.6 million compared to $67.0 million in the same period last year, attributed to high interest rates and weak consumer demand [58]. Product Development and Innovation - The launch of Universkin, an AI-powered personalized skincare system, has gained rapid market recognition in North America, enhancing long-term customer relationships and retention [18]. - Alma IQTM, a smart imaging device, has received positive feedback globally, improving diagnostic accuracy and overall patient experience [18]. - The company is preparing for the launch of its patented long-acting botulinum toxin product, DaxibotulinumtoxinA, in mainland China, including the establishment of a professional sales team [19]. - The strategic partnership with Hallura for the commercialization of innovative hyaluronic acid and biostimulant combination products is progressing well [18]. - The company is actively commercializing the injectable A-type botulinum toxin product, DaxibotulinumtoxinA-lanm, in collaboration with Fosun [44]. - The company plans to launch the world's first peptide-powered botulinum toxin product in mainland China and expand its energy source equipment offerings in the Chinese market [52]. Financial Performance - For the first half of 2025, the total revenue was $165.5 million, a decrease of 1.9% compared to the same period in 2024 [28]. - Gross profit for the first half of 2025 was $99.3 million, down 5.7% year-over-year, with a gross margin of 60.0%, a decline of 2.4 percentage points from 62.4% in 2024 [28]. - The company achieved a profit before tax of $11.8 million and a net profit of $9.0 million for the first half of 2025, representing decreases of 19.9% and 31.9% respectively compared to the same period in 2024 [28]. - Adjusted net profit for the first half of 2025 was $12.0 million, down 28.1% year-over-year, with an adjusted net profit margin of 7.2%, a decrease of 2.7 percentage points from 2024 [29]. - The company reported a solid order reserve as of June 30, 2025, with an increase of several million dollars compared to the same period in 2024 [53]. - The company anticipates stronger performance in revenue and net profit in the second half of 2025 compared to the first half, supported by increased order volumes and the expected launch of a patented long-acting botulinum toxin product in mainland China [22]. Strategic Initiatives - Sisram Medical continues to focus on integrating technology and product offerings, enhancing its core energy source and injection filling businesses [10]. - The company is advancing its ecological layout by promoting a beauty and health ecosystem, integrating medical and consumer scenarios [12]. - The company aims to build a global aesthetic medical ecosystem platform, focusing on unmet clinical needs and accelerating the transformation from R&D to market [16]. - The company is focusing on strategic capacity expansion to meet the growing global demand, particularly for core medical energy source equipment products [47]. - The company plans to accelerate the sales promotion of the Revanesse series of dermal fillers in the UK, Ireland, DACH region, Australia, and New Zealand, while expanding the Profhilo flagship bioremodeling therapy in various Asian markets [23]. Cash Flow and Financial Position - Cash and bank balances stood at $60.3 million as of June 30, 2025, compared to $70.2 million at the end of 2024, indicating a need for careful cash management [26]. - The net cash flow used in operating activities for the six months ended June 30, 2025, was $(4,891,000), compared to $3,961,000 for the same period in 2024, showing a decline of 223.5% [108]. - The total assets as of June 30, 2025, were $633.3 million, with total liabilities of $145.6 million, reflecting a solid financial position [26]. - The company reported R&D expenses of $8.1 million during the reporting period [33]. - The company raised $18,650,000 in new bank loans during the six months ended June 30, 2025, compared to $2,828,000 in the same period of 2024 [108]. Market Trends and Challenges - The company’s operating performance is sensitive to foreign currency exchange rate changes, particularly due to its revenue being primarily in USD and costs in multiple currencies [96]. - The direct sales strategy in the Asia-Pacific region has shown significant improvement, particularly in Thailand and South Korea [42]. - The company is enhancing its global customer relationship management (CRM) system and investing in data analytics to improve customer support and supply chain management [48]. - The company has made significant progress in intellectual property, including multiple new patents in the fields of radiofrequency and ultrasound [38]. - The company is exploring partnerships with international firms to enhance its global footprint [163].

Summary of Sisram Medical (1696.HK) Conference Call Company Overview - **Company**: Sisram Medical - **Industry**: Medical Equipment and Aesthetic Injectables Key Points 1. Business Transformation and Growth Strategy - Sisram Medical has transitioned from a wholesale to a direct sales model over the past few years, laying out a growth roadmap for 2025 and beyond [2][8] - The core business, energy-based equipment, currently contributes 90% of revenue, with a target to reduce this to 60% in five years [2][9] - The company plans to upgrade traditional products, increase the mix of consumables, and expand use cases beyond skincare [2][6] 2. Product Development and Market Projections - **Energy-Based Equipment**: Focus on upgrading products like Intense Pulsed Light, Radio Frequency, and Laser [3][6] - **Injectables**: Currently contributing 10% of revenue, with a target to increase to 40% in five years. The product pipeline includes: - **DAXXIFY**: Expected launch in China in 2H25, projected to generate RMB100 million in sales in 2026 and a cumulative RMB1-2 billion over the next 3-5 years, targeting a 30% market share in the high-end BTX market [2][9] - **Profhilo**: Anticipated approval in China by the end of next year, expected to generate RMB300-500 million in annual sales [2][9] 3. Synergies Between Product Lines - Management believes that once both energy-based equipment and injectables are established, combined treatment solutions can be marketed to clinics, enhancing outcomes and branding [8][9] 4. Sales and Market Outlook - Management expects year-over-year growth in sales, net income, and net profit margin in 2025, with acceleration into 2026, primarily driven by the Titanium Lifting devices and injectables [2][8] - The Titanium Lifting device is gaining traction, with management projecting 200-300 orders in 2025 and 600-700 in 2026, each order valued at RMB800-900k [9] 5. Sales Channel and Regional Focus - Sisram has shifted from distribution to direct sales since 2017, now operating 12 direct sales points globally. This shift is expected to improve margins [9] - Long-term sales targets include USD100-150 million in China/US, USD50 million in the UK, USD30 million in Japan/Korea, and USD10 million in smaller regions [9] 6. Financial Performance Expectations - Management anticipates improving sales and net income performance into 2025 and beyond, driven by the growth of both the Titanium Lifting devices and injectables [8][9] Additional Insights - The company is focusing on expanding use cases for its products, including anti-aging, body treatments, sexual wellness, and hair growth [6] - The strategic shift towards direct sales is expected to enhance profitability and customer engagement [9] This summary encapsulates the key takeaways from the Sisram Medical conference call, highlighting the company's strategic direction, product development, and market outlook.

Core Viewpoint - Alma Lasers Ltd., a wholly-owned subsidiary of Foryou Medical Technology (01696.HK), has entered into a strategic partnership with renowned skincare expert Jamie Sherrill, also known as Nurse Jamie, to enhance consumer engagement and solidify its leadership in high-end aesthetic technology [1]. Company Summary - The collaboration with Nurse Jamie is expected to increase consumer awareness of Alma's high-end solutions [1]. - This partnership aims to create stronger demand for Alma's offerings among global clinic partners and explore new growth opportunities [1].

Core Viewpoint - Alma Lasers Ltd., a wholly-owned subsidiary of Revance Therapeutics (01696), has entered into a strategic partnership with renowned skincare expert Jamie Sherrill, enhancing its position in the high-end aesthetic technology market [1] Group 1: Strategic Partnership - The collaboration with Jamie Sherrill aims to improve consumer engagement and solidify Alma's leadership in aesthetic technology [1] - Jamie Sherrill will serve as a strategic ambassador for Alma's flagship device platforms, including Alma Harmony and Opus series, leading global promotional activities [1] Group 2: Market Impact - The partnership is expected to increase consumer awareness of Alma's high-end solutions and create stronger demand for global clinic partners [1] - The collaboration is anticipated to open new growth opportunities for the company in the consumer market [1]

Core Viewpoint - Alma Lasers Ltd. has entered into a strategic partnership with renowned skincare expert Jamie Sherrill to enhance consumer engagement and solidify its leadership in high-end aesthetic technology [1] Group 1: Strategic Partnership - The partnership aims to leverage Jamie Sherrill's influence in the aesthetic field to promote Alma's flagship equipment platforms, including Alma Harmony and Opus series [1] - Jamie Sherrill will lead global promotional activities to increase the brand's global recognition and accelerate market penetration of Alma's aesthetic solutions [1] Group 2: Market Impact - The collaboration is expected to enhance consumer awareness of Alma's high-end solutions and create stronger demand for global clinic partners, opening new growth opportunities [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因依 賴該等內容而引致的任何損失承擔任何責任。 （ 於 以 色 列 註 冊 成 立 的 有 限 公 司 ） （股份代號：1696） 自願公告 本公告乃由復銳醫療科技有限公司（「本公司」）自願發佈。 Sisram Medical Ltd 復䢇醫療科技有限公司* 本公司欣然宣佈，本公司全資附屬公司，專注於能量源醫美設備美學解決方案提 供商，Alma Lasers Ltd.（「Alma」）與國際知名皮膚護理專家、企業家及醫美領域 廣受認可的國際意見領袖Jamie Sherrill（「Nurse Jamie」）達成戰略合作。此次合作 標誌著Alma在提高消費者互動，鞏固其高端美學技術領導地位的戰略部署中邁出 重要一步。 股東及投資者於買賣本公司證券時務請審慎行事。 代表董事會 Sisram Medical Ltd 復銳醫療科技有限公司* 主席 劉毅 Jamie Sherrill是一名專注美學領域的註冊護士，憑藉循證醫學理念和創新治療方 案，在線上擁有廣泛的影 ...

股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 致：香港交易及結算所有限公司 公司名稱: Sisram Medical Ltd 復銳醫療科技有限公司* 呈交日期: 2025年9月3日 FF301 第 1 頁 共 10 頁 v 1.1.1 FF301 II. 已發行股份及/或庫存股份變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 01696 | 說明 | | | | | | | | | 已發行股份（不包括庫存股份）數目 | | 庫存股份數目 | | 已發行股份總數 | | | 上月底結存 | | | 468,343,092 | | 0 | | 468,343,092 | | 增加 / 減少 (-) | | | 0 | | 0 | | | | 本月底結存 | | | 468,343,092 | | 0 | | 468,343,092 | ...

Core Viewpoint - The company reported its 1H25 performance, which met expectations despite a slight decline in overall revenue, with specific growth in non-North American markets [1][2]. Revenue Performance - Total revenue for 1H25 was $165 million, a year-on-year decrease of 1.9% [1]. - Revenue by region showed robust growth outside North America, with Asia-Pacific revenue at $65.82 million (YoY +17.6%), North America at $56.60 million (YoY -15.6%), Europe at $23.83 million (YoY -0.8%), Middle East and Africa at $13.91 million (YoY -9.7%), and Latin America at $5.32 million (YoY -15.8%) [1]. Business Segments - Medical aesthetics revenue for 1H25 was $138 million, down 7.8%, primarily due to economic challenges in North America and the Middle East and Africa [2]. - Injection filler revenue surged to $14.38 million, reflecting a 218.1% increase, driven by expanded sales regions and direct sales networks [2]. - Service and other revenue decreased to $13.40 million, down 9.9% [2]. Product Pipeline and Commercialization - The company is expanding its product pipeline, with expectations for the commercialization of DaxibotulinumtoxinA (long-acting botulinum) in mainland China in the second half of the year [2]. - The company launched Universkin by Alma, the world's first AI-assisted personalized skincare system, which has seen rapid uptake in the U.S. market [2]. Profit Forecast and Valuation - Due to revenue pressures in certain overseas markets, the company has revised its adjusted net profit forecasts for 2025 and 2026 down by 24.3% and 19.8% to $36.05 million and $41.49 million, respectively [2]. - The current stock price corresponds to adjusted P/E ratios of 9.6x and 8.3x for 2025 and 2026, with a target price maintained at HKD 6.00, implying a potential upside of 5.3% [2].

Investment Rating - The report maintains a "Buy" rating for the company [3][9][17] Core Views - The company's performance is temporarily under pressure due to external factors, particularly in North America, but there is optimism for recovery as the innovation pipeline progresses [3][16] - Revenue for H1 2025 was reported at $165 million, a slight decrease of 1.93% year-on-year, with adjusted net profit down 28.13% to $11.97 million [12][13] - The company is expected to see revenue growth from $395 million in 2025 to $530 million by 2027, with corresponding net profits increasing from $31.5 million to $57.39 million [3][11][17] Summary by Sections Financial Performance - H1 2025 revenue breakdown: - Asia-Pacific: $66 million (+17.64%), contributing 39.78% of total revenue - North America: $57 million (-15.56%), contributing 34.20% - Europe: $24 million (-0.84%), contributing 14.40% - Middle East & Africa: $14 million (-9.72%), contributing 8.41% - Latin America: $5 million (-15.83%), contributing 3.21% [2][13] - Medical aesthetics revenue was $138 million (-7.79%), while injection filling revenue surged to $14 million (+218.15%) [2][13] Cost and Profitability - The company's gross margin for H1 2025 was 60.04%, down 2.38 percentage points, with adjusted net profit margin at 7.23% [15] - Management expenses increased, leading to a slight rise in expense ratios, with total expenses at $11.97 million [14][15] Future Outlook - The energy source equipment business is expected to stabilize and grow as external conditions improve, with new product launches planned for H2 2025 [16][17] - The long-acting botulinum toxin product is anticipated to launch by the end of 2025, which could significantly enhance market recognition and sales [3][17]